`TOTAL PRESCRIPTIONS
`U.S. UNITS BY PRODUCT
`Q4 2012 – Q3 2014
`
`IV
`Herceptin®
`Kadcyla®¹
`Perjeta®
`
`
`
`Total
`
`IV
`Herceptin®
`Kadcyla®
`Perjeta®
`
`
`
`Total
`
`
`
`
`
`2012
`
`Q4
`
`1,024
`
`140
`
`
`
`1,164
`
`88.0%
`
`12.0%
`
`
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`1,051
`14
`180
`
`1,245
`
`84.4%
`1.1%
`14.5%
`
`
`
`
`
`992
`145
`214
`
`1,351
`
`73.4%
`10.7%
`15.8%
`
`
`
`
`
`1,057
`257
`187
`
`1,501
`
`70.4%
`17.1%
`12.5%
`
`
`
`
`
`1,034
`314
`217
`
`1,565
`
`66.1%
`20.1%
`13.9%
`
`
`
`
`
`1,070
`299
`315
`
`1,684
`
`63.5%
`17.8%
`18.7%
`
`
`
`
`
`1,200
`275
`333
`
`1,808
`
`66.4%
`15.2%
`18.4%
`
`
`
`
`
`1,071
`203
`287
`
`1,561
`
`68.6%
`13.0%
`18.4%
`
`
`
`
`
`8,499
`1,507
`1,873
`
`11,879
`
`71.5%
`12.7%
`15.8%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`Notes & Sources:
`¹ Annual Kadcyla® prescriptions totaled 730 in 2013.
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand values.
`Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Values reflect field 'TRx'.
`Percentage calculated as percent of quarterly total.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2256, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`